VIENNA, Va., June 19 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION will conduct a live interview on http://www.MN1.com at 11:00 a.m. eastern time this Tuesday, June 20, 2006. Interested parties may go to http://www.MN1.com to listen to management’s review of operations and discussion of future prospects. This live broadcast is available to anyone at any computer connected to the Internet.
MN1.com is the only online destination that brings real microcap news to investors and features live interaction with companies from the AMEX, Bulletin Board, and Pink Sheets. Featuring Live Press Conferences, All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and “The MicroBlog,” MN1.com gives microcap investors the information source necessary to trade in the markets. MN1.com boasts being the largest true news company reporting on microcap traded stocks.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company’s lead product Multikine is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI’s other products, which are currently in pre- clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
CEL-SCI Corporation
CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460
